Condensed Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Operating activities:
Net loss	$ (26,525)	$ (16,780)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,126	606
Net amortization of premiums on marketable securities	418	766
Amortization of debt discount	262	38
Amortization of loan fees	73	5
Stock-based compensation expense	4,005	3,990
Loss from equity method investment	959
Revaluation of warrant liability	(54)
Revaluation of derivative liability	737
Changes in operating assets and liabilities:
Accounts receivable	(4,040)	(2,675)
Unbilled revenue	874	906
Inventories	222	(952)
Prepaid expenses and other current assets	485	905
Accounts payable	(2,129)	(2,364)
Accrued liabilities	2,724	(2,921)
Deferred revenue	3,142	(164)
Other current and long-term liabilities	(499)	8
Net cash used in operating activities	(18,220)	(18,632)
Investing activities:
Purchases of property, plant and equipment	(1,189)	(4,752)
Purchases of marketable securities	(83,581)	(38,979)
Maturities of marketable securities	17,618	46,565
Proceeds from sales of marketable securities		5,409
Capital contribution in unconsolidated joint venture	(5,500)
Net cash (used in) provided by investing activities	(72,652)	8,243
Financing activities:
Repayments under loan agreements	(14,872)	(2,743)
Proceeds from the issuance of senior subordinated convertible notes, net of debt discount	119,750
Proceeds from the issuance of common stock, net of repurchases	260	1,444
Proceeds from issuance of common stock, pursuant to ESPP	516
Early exercise of stock options subject to repurchase	(8)	(17)
Proceeds from borrowings under loan agreements	10,369
Payment for loan costs and fees	(500)
Net cash provided by (used in) financing activities	115,515	(1,316)
Effect of exchange rate changes on cash and cash equivalents	(21)	(86)
Net increase (decrease) of cash and cash equivalents	24,622	(11,791)
Cash and cash equivalents - beginning of period	30,818	28,780
Cash and cash equivalents - end of period	55,440	16,989
Supplemental disclosures of cash flow information:
Interest paid in cash	183	187
Income taxes paid in cash
Supplemental disclosure of noncash investing and financing activities:
Capital assets in accounts payable and accrued liabilities	502	1,500
Debt issue costs in accounts payable and accrued liabilities	118
Change in unrealized (loss) gain on marketable securities	(69)	561
Common stock issued in lieu of cash bonus	$ 121
Common stock issued in connection with use and operation of third party manufacturing facility	2,655